Date: 2018-09-06
Type of information: Collaboration agreement
Compound: atezolizumab (Tecentriq®)
Company: Oncolytics Biotech (Canada) Roche (Switzerland)
Therapeutic area:
Type agreement: collaboration - supply agreement
Action mechanism:
- immunotherapy product/monoclonal antibody/immune checkpoint inhibitor. Atezolizumab is a monoclonal antibody designed to make cancer cells more vulnerable to the body’s immune system by interfering with a protein called PD-L1. PD-L1 is found on the surface of cells in tumours and is believed to act as a “stop sign,” preventing the immune system from destroying cancer cells. By inhibiting PD-L1, atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
Disease:
Details:
- • On September 6, 2018, Oncolytics Biotech® announced that it has entered into a Master Clinical Supply Agreement (Agreement) with Roche to supply atezolizumab (Tecentriq®) for use in the company’s clinical development program.
- Oncolytics Biotech plans to further investigate pelareorep’s impact on cancer treatments in combination with atezolizumab. Pelareopep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus being evaluated for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers
- Under this five-year Master Clinical Supply Agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.
Financial terms:
Latest news:
Is general: Yes
